Agenus (AGEN)
(Delayed Data from NSDQ)
$6.26 USD
+0.33 (5.56%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $6.26 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Brokerage Reports
Agenus Inc. [AGEN]
Reports for Purchase
Showing records 141 - 160 ( 262 total )
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Update; Advancing Multiple Checkpoint Modulators to the Finish Line
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
QS-21 Still Driving Interest; Adjusting Model; Target Lowered to $12.50
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Prophage Traction Continues to Strengthen; Target Upped to $15
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
GSK''s MAGE Program Gets Kicked in the Shin
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
2Q13 Results; Calm Before the Storm....of News; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - AVAglio Data Unimpressive; Cancer Vaccine Approaches Continue to Be Favored
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Alliance Study of Prophage Begins, as Expected; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
Positive Interim Results for Prophage;Alliance Study to Start Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Results; Looking Towards Prophage Data in Frontline GBM on May 1st
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Agenus Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.